• share
• favorite_border

Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a biodegradable polymer compared to thin-strut everolimus-eluting stents (Xience EES) with a durable polymer in terms of in-segment late lumen loss in successfully treated chronic total occlusions. In addition, although the rate of binary restenosis was low overall in this complex lesion subset, it was higher with the Osirio SES compared with the Xience EES.

• share
• favorite_border

Results from the U.S. real-world, post-FDA approval experience of the Watchman device found high procedural success and low complication rates despite implantations by a large percentage of new operators. The Watchman device was approved by the U.S. Food and Drug Administration (FDA) in March 2015 for left atrial appendage occlusion (LAAC) to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AF).

• share
• favorite_border

Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OCT) to evaluate strut coverage and neoatherosclerosis (NA) found that bioresorbable polymer-based drug-eluting stents (BP-EES) are comparable to durable polymer-based drug-eluting stents (DP-ZES).

• share
• favorite_border

Initial results from the largest, prospective evaluation of a percutaneous transcatheter left atrial appendage (LAA) closure device (Amplatzer Amulet) for stroke prevention in patients with non-valvular atrial fibrillation show that the device has a high implant success rate and low major adverse events.

• share
• favorite_border

A randomized evaluation of routine follow-up coronary angiography after percutaneous coronary intervention (PCI) found that there was no long-term clinical benefit compared to clinical follow-up alone among unselected patients following PCI.

• share
• favorite_border

A dedicated stent study conducted exclusively in women and minority patients evaluated clinical outcomes within the era of contemporary PCI, comparing these results to a parallel cohort of white male patients. Although there were no significant differences in stent-related outcomes, both groups had higher rates of death and myocardial infarction (MI) in the first year following the procedure.

• share
• favorite_border

Final results from the RESPECT trial found that percutaneously closing a patent foramen ovale (PFO) using the Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent ischemic stroke in patients who previously had a cryptogenic stroke.

• share
• favorite_border

Two-year results from COLOR, the first large-scale multicenter prospective study of its kind, found that PCI on coronary artery lipid-rich plaque (LRP) detected by near infrared spectroscopy (NIRS) was not associated with subsequent major adverse cardiac events (MACE) compared to PCI of non-LRPs.

• share
• favorite_border

A substudy of the PARTNER I Trial and Continued Access Registry found that hemodynamic trends in patients who received transcatheter aortic valve replacement (TAVR) showed excellent durability without significant structural valve deterioration at five years. The trial represents the largest to-date longitudinal analysis of echocardiographic hemodynamic parameters systematically assessed by a core laboratory.

• share
• favorite_border

Patients with severe aortic stenosis (AS) at intermediate surgical risk, and who are treated with transcatheter aortic valve replacement (TAVR) had improved health status at one month compared with surgical aortic valve replacement (SAVR) but two-year quality of life outcomes were similar. Prior studies have shown that TAVR results in an early quality of life (QoL) benefit in patients at high surgical risk; however, the effect of TAVR versus. SAVR on QoL in intermediate risk patients was unknown prior to this study.

• share
• favorite_border

A multicenter randomized trial evaluating the role of embolic protection using the Sentinel device during transcatheter aortic valve replacement (TAVR) found that the device was safe but did not meet the primary efficacy endpoint of reduction in median new lesion volume in protected territories assessed by MRI at 2-7 days. In addition, neurocognitive function was not significantly improved.

• share
• favorite_border

The 28th annual Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) featured a number of first report investigations on novel stents that could become the next generation of bioresorbable stents in patients.

• share
• favorite_border

A first-in-human study of a new polymer-free drug-filled stent, which provides controlled drug elution from an internal lumen, indicated non-inferior in-stent late lumen loss at nine-months compared with historical zotarolimus-eluting stent (Resolute) data. In addition, there was no binary restenosis, and a high degree of early stent strut coverage with minimal malapposition.

• share
• favorite_border

A large-scale randomized trial examining percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) in patients with left main coronary artery disease (LMCAD) and low-intermediate SYNTAX scores found that there was no significant difference in three-year outcomes between the two treatments, with a reduction in 30-day major adverse events with PCI.

• share
• favorite_border

Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. Findings from the Nordic–Baltic–British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease.

• share
• favorite_border

The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high bleeding risk patients treated with one month of dual antiplatelet therapy (DAPT), found that a polymer-free drug-coated stent (DCS) remained both significantly safer and more effective than the comparator bare-metal stent (BMS) used in the trial.

• share
• favorite_border

Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in treating an all-comers population with a high proportion of patients with acute coronary syndromes.

• share
• favorite_border

Although percutaneous coronary intervention (PCI) is most commonly guided by angiography alone, results from a new study investigating adjunctive imaging modalities showed that the use of a novel optical coherence tomography (OCT)-based stent sizing strategy results in similar minimal stent area (MSA) compared to intravascular ultrasound (IVUS)-guided PCI. Imaging-guided PCI (with both OCT and IVUS) also resulted in improved stent expansion and acute stent-based procedural success compared to angiography-guided PCI.

• share
• favorite_border

The large multinational randomized BIONICS study found that a novel ridaforolimus-eluting stent (BioNIR) was non-inferior to a zotarolimus-eluting stent (Resolute) for one-year clinical outcomes in a broad, less selected ‘more comers’ population. Results of this trial will be submitted to the FDA for U.S. approval of this novel drug-eluting stent.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) is pleased to announce the launch of a new international journal focusing on the diagnosis and treatment of structural heart disease and the importance of the heart team in managing these disorders.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) is pleased to announce the launch of the new TCTMD (www.tctmd.com), the leading online resource for cutting-edge news and information in interventional cardiology and beyond.

• share
• favorite_border

The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF) will feature a number of first-in-human and early feasibility trials that could impact future clinical practice. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2, 2016 at the Walter E. Washington Convention Center in Washington, DC.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2 in Washington, DC.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2, 2016 at the Walter E. Washington Convention Center in Washington, DC.

• share
• favorite_border

Earvin “Magic” Johnson will be a special keynote speaker at TCT 2016 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine, attracting nearly 12,000 attendees from all over the world.

• share
• favorite_border

TCT (Transcatheter Cardiovascular Therapeutics), is the annual Scientific Symposium of the Cardiovascular Research Foundation (CRF). It is the world’s premier educational meeting specializing in interventional cardiovascular medicine and attracts nearly 12,000 attendees from all over the world. Every year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

• share
• favorite_border

TVT 2016 is a three-day course featuring the latest research and state-of-the-art techniques for transcatheter aortic and mitral valve therapies. This year’s conference will emphasize advanced imaging, bioskill demonstrations, and live case transmissions featuring the world’s leading experts.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF), a nonprofit organization dedicated to heart disease research and education, has announced it will be moving its corporate office to a new location in midtown Manhattan.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF), a nonprofit organization dedicated to heart disease research and education, launched a new logo and website today.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) announced today that Daniel Burkhoff, MD, PhD, has returned to the organization as Director of Heart Failure, Hemodynamics and Circulatory Support in the CRF Clinical Trials Center (CTC).

• share
• favorite_border

Physicians and fellows from the Cardiovascular Research Foundation (CRF) will be presenting abstracts at the American College of Cardiology 65th Annual Scientific Session taking place April 2-4, 2016 at McCormick Place in Chicago, IL. They will be sharing the latest data on drug-eluting stents, imaging technologies, dual antiplatelet therapy, transcatheter aortic valve replacement, and bioresorbable vascular scaffolds.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) is excited to announce the launch of TCTMD’s new podcast network, the Pulse of Cardiology. TCTMD is the leading online resource for cutting-edge news and information in interventional cardiovascular medicine, and beyond.

• share
• favorite_border

The CTO Summit 2016 is a two-day course featuring the latest research and state-of-the-art technologies for chronic total occlusions. This year’s conference will emphasize advanced techniques, evidence-based medicine, and live case transmissions featuring the world’s leading experts in CTO stenting. Sessions showcasing the latest research on CTOs will focus on procedural outcomes, registry updates, and new stent technologies.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) is pleased to announce that Michael O’Riordan joins the organization today as Senior Editorial Journalist for TCTMD, the leading online resource for cutting-edge news and information in interventional cardiovascular medicine.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) has joined #GivingTuesday, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide. This year 100% of the donations to CRF made on Giving Tuesday will go directly to the CRF Fellows Fund, which was established to mentor the next generation of cardiovascular researchers and provide financial support for the rapid advancement of breakthrough treatments needed in the fight against heart disease, the #1 killer of men and women worldwide.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) announced today that Shelley Wood will join the organization as Editorial Director on October 15. Ms. Wood will lead CRF’s editorial services department and be responsible for developing original, thought-provoking, and clinically relevant content for TCTMD, the leading online resource for cutting-edge news and information in interventional cardiovascular medicine. She will also play an integral role in ongoing enhancements of the TCTMD website.

• share
• favorite_border

Noteworthy data will be presented at Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium next month on several trials examining the use of cardiovascular stents (or “scaffolds”) that are absorbed back into the body over time.

• share
• favorite_border

CRF has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the TCT 2015 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 11-15, 2015 in San Francisco, California.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) announced that Jason Ware has joined the organization as Director, Meeting Planning. In this role, Ware oversees the meeting planning function of the CRF Center for Education. His responsibilities include managing a staff of meeting planners and working with vendors and internal resources to execute the logistics for CRF educational meetings throughout the year.

• share
• favorite_border

To honor the life and work of Dr. Michael Davidson, the Cardiovascular Research Foundation (CRF) has partnered with the San Francisco Giants to host the Dr. Michael Davidson 5K Run/Walk during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine.

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) has announced the late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific symposium.

• share
• favorite_border

Novella Clinical and the CRF Clinical Trials Center will conduct webinar on how medical device developers can avoid the pitfalls and challenges of conducting cardiovascular clinical trials.

• share
• favorite_border

Data from the ILUMIEN II trial found that guidance from optimal coherence tomography (OCT) was associated with comparable stent expansion as guidance from intravascular ultrasound (IVUS) in patients undergoing percutaneous coronary intervention (PCI). Results from the study were presented today at EuroPCR 2015, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

• share
• favorite_border

TVT 2015 is a three-day course featuring the latest research and state-of-the-art techniques for transcatheter, aortic, and mitral valve therapies. This year’s conference will emphasize advanced imaging, bioskill demonstrations, and live case transmissions featuring the world’s leading experts.

• share
• favorite_border

TCT 2015 (Transcatheter Cardiovascular Therapeutics) is the annual Scientific Symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

• share
• favorite_border

Data from a meta-analysis published today in The Lancet found that extended duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with significantly higher rates of mortality compared to shorter DAPT.

• share
• favorite_border

Data from the BRIGHT trial published today in the Journal of the American Medical Association demonstrated that bivalirudin was superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Findings were first reported at last year’s Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).

• share
• favorite_border

The CTO Summit 2015 is a two-day course featuring the latest research and state-of-the-art technologies for chronic total occlusions.

• share
• favorite_border

Novella Clinical, a Quintiles company (Novella), and the Cardiovascular Research Foundation (CRF) today announced a preferred provider collaboration that will offer a set of clinical trial services to developers of cardiovascular drugs and devices.

• share
• favorite_border

A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. Results of this study were published today in The Journal of Clinical Investigation.